Literature DB >> 91781

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

R Y Calne, K Rolles, D J White, S Thiru, D B Evans, P McMaster, D C Dunn, G N Craddock, R G Henderson, S Aziz, P Lewis.   

Abstract

34 patients treated with cyclosporin A received 36 cadaveric organ allografts (32 kidneys, 2 pancreases, and 2 livers), 26 kidneys are still supporting life, 3 after more than a year; the pancreases and livers are also functioning. 20 patients are not receiving steroids, and 15 of these have not had any additional immunosuppressive agents. In these patients infectious complications have not been severe, but a gastroduodenal lymphoma has developed in 1 patient. 6 patients were given 'Cytimum' (a cyclophosphamide derivative) and steroids in addition to cyclosporin A: 5 of these died of infections and 1 also had a lymphoma. 11 patients received additional steroids: 1 of these died from septicaemia and lymphoma. Nephrotoxicity can be avoided by perioperative hydration and forced diuresis. Cyclosporin A is effective on its own and is a very potent immunosuppressive drug. Additional immunosuppressive agents may lead to severe complications.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 91781     DOI: 10.1016/s0140-6736(79)92440-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  215 in total

1.  The ascension of clinical organ transplantation.

Authors:  T E Starzl
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

2.  The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967).

Authors:  Thomas E Starzl
Journal:  J Am Coll Surg       Date:  2002-11       Impact factor: 6.113

3.  History of clinical transplantation.

Authors:  T E Starzl
Journal:  World J Surg       Date:  2000-07       Impact factor: 3.352

4.  Cyclosporin A effective therapy for fifty-two cadaver kidney recipients.

Authors:  H Takagi; K Uchida; S Ohshima; T Fujita; T Kano; H Asano; Y Ono
Journal:  Jpn J Surg       Date:  1985-03

5.  Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids.

Authors:  T E Starzl; T R Hakala; J T Rosenthal; S Iwatsuki; B W Shaw
Journal:  Surg Gynecol Obstet       Date:  1982-06

Review 6.  Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.

Authors:  Agnieszka Swiatecka-Urban
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  Thirty months' experience with cyclosporin in human pancreatic transplantation.

Authors:  J Traeger; E Bosi; J M Dubernard; J L Touraine; P M Piatti; A Secchi; A Gelet; G Pozza
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

8.  Experience with cyclosporine and steroids in clinical renal transplantation.

Authors:  N L Tilney; E L Milford; J L Araujo; T B Strom; C B Carpenter; R L Kirkman
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

9.  Early results of cardiac transplantation at the Texas Heart Institute.

Authors:  I J Reece; O H Frazier; A Painvin; O J Okereke; L B Chandler; T W Krudewig; D A Cooley
Journal:  Thorax       Date:  1984-09       Impact factor: 9.139

10.  Prevention of diabetes mellitus in the BB/W rat with Cyclosporin-A.

Authors:  A A Like; V Dirodi; S Thomas; D L Guberski; A A Rossini
Journal:  Am J Pathol       Date:  1984-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.